IntelGenx Technologies Corporation (IGXT)

OTCMKTS: IGXT · Delayed Price · USD
-0.008 (-4.88%)
Jul 5, 2022 4:00 PM - Market closed

Company Description

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.

It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.

It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

IntelGenx Technologies Corporation
IntelGenx Technologies Logo
Country Canada
Founded 2003
Industry Pharmaceuticals
Sector Health Care
Employees 4
CEO Horst Zerbe

Contact Details

6420 Abrams St
Saint Laurent, Quebec H4S 1Y2
Phone 514 331 7440

Stock Details

Ticker Symbol IGXT
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001098880
CUSIP Number 45822R101
ISIN Number US45822R1014
Employer ID 87-0638336
SIC Code 2834

Key Executives

Name Position
Dr. Horst G. Zerbe Ph.D. Chairman, Chief Executive Officer and Chairman of Scientific Advisory Board
André Godin C.A., CPA, CA, CPA President and Chief Financial Officer
Tommy Kenny J.D., L.L.B., M.Sc. Vice President of Intellectual Property and Legal Affairs and General Counsel
Nadine Paiement Vice-Chair of Scientific Advisory Board and Vice President of Research & Development - IntelGenx Corp
Stephen Kilmer Investor Relations Officer
Ingrid Zerbe Corporate Secretary

Latest SEC Filings

Date Type Title
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 11, 2022 8-K Current report
Apr 20, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 31, 2022 4 Statement of changes in beneficial ownership of securities
Mar 24, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 24, 2022 DEF 14A Other definitive proxy statements
Mar 21, 2022 8-K Current report
Dec 8, 2021 8-K Current report
Nov 10, 2021 10-Q Quarterly report [Sections 13 or 15(d)]
Sep 15, 2021 8-K Current report